European Pharmaceutical Review

OCTOBER 24, 2023

billion in 2028, according to a report by Arizton. percent up to 2028. percent between the forecast period: 2023 and 2028. percent between the forecast period 2023-2028. Europe’s pharmaceutical packaging and labelling market is projected to reach $35.78 Having been valued at $27.04 percent in 2022. percent in 2022.

Pharmaceutical 118

Pharmaceutical Marketing Medicine Pharmaceutical Sales 118

Pharmaceutical Technology

MAY 30, 2023

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028.

Sales 105

Sales Marketing Prescription Pharma 105

pharmaphorum

JUNE 27, 2022

per share for Cambridge, Massachusetts-based Epizyme – valuing the US company at around $247 million – and is also promising a further contingent value right (CVR) payment of up to $1 per share if Tazverik (tazemetostat) achieves certain development and sales targets. Ipsen is offering $1.45 Ipsen’s CVR offer includes $0.30

Biopharma 95

Biopharma Sales Prescription FDA 95

World of DTC Marketing

MARCH 17, 2021

sales until at least 2023 because 257 patent filings stand in the way. Another biologic, Enbrel, on the market since 1998, will not have its $5 billion in sales challenged until the end of 2028. For 2020, AbbVie’s handing its longtime CEO $24 million in total pay, up from 2019’s $21.6

Pharma 186

Pharma Competition Prescription Sales 186

Clarivate

OCTOBER 25, 2023

While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. With 27.5%

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

PM360

SEPTEMBER 21, 2023

As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. CMS will present an initial offer for each drug’s maximum fair price (MFP) by February 1, 2024.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

PM360

SEPTEMBER 21, 2023

Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re

Management 105

Management Manufacturing Sales Competition 105